+关注
ReaganMama
暂无个人介绍
IP属地：未知
4
关注
0
粉丝
0
主题
0
勋章
主贴
热门
ReaganMama
2021-06-14
Great!
Moderna Inks Partnership Deal with Tabuk Pharmaceuticals
ReaganMama
2021-06-14
Done
抱歉，原内容已删除
ReaganMama
2021-06-14
Great!
抱歉，原内容已删除
ReaganMama
2021-06-14
Wow, how getting better
抱歉，原内容已删除
ReaganMama
2021-03-17
nice
抱歉，原内容已删除
ReaganMama
2021-03-17
gogo！
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577012862693100","uuid":"3577012862693100","gmtCreate":1615956664882,"gmtModify":1623683744427,"name":"ReaganMama","pinyin":"reaganmama","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":184092857,"gmtCreate":1623677260679,"gmtModify":1634030238160,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184092857","repostId":"2143781157","repostType":4,"repost":{"id":"2143781157","pubTimestamp":1623660416,"share":"https://www.laohu8.com/m/news/2143781157?lang=&edition=full","pubTime":"2021-06-14 16:46","market":"us","language":"en","title":"Moderna Inks Partnership Deal with Tabuk Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2143781157","media":"SmarterAnalyst","summary":"The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharma","content":"<p>The pharmaceutical and biotechnology company <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> (<b>MRNA</b>) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session.</p>\n<p>The financial terms of the deal have not been disclosed.</p>\n<p>Per the agreement, Tabuk could get the opportunity to distribute other authorized Moderna mRNA products in the future.</p>\n<p>Tabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, is a Saudi pharmaceuticals company.</p>\n<p>Moderna CEO Stephane Bancel said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia.”</p>\n<p>Bancel further added, “It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.” (See Moderna stock analysis on TipRanks)</p>\n<p>On June 10, Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on the stock but increased the price target to $224 (2.4% upside potential) from $205.</p>\n<p>Cann commented, “For a company at Moderna’s stage of development, which is largely pre-approval, we primarily focus on potential future revenue to value the company. Based on our expectation that in addition to its already launched COVID-19 vaccine, Moderna will launch several of its development-stage products in the next six years, we estimate that Moderna’s total revenue will increase to $100.1 billion in 2030.”</p>\n<p>The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 6 Buys, 3 Holds, and 2 Sells. The MRNA average analyst price target of $194 implies 11.4% downside potential to current levels. Shares have increased 41.1% over the past six months.</p>\n<p><img src=\"https://static.tigerbbs.com/a7b9b1c14597ff8c93148627f4cdbe23\" tg-width=\"825\" tg-height=\"286\" referrerpolicy=\"no-referrer\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Inks Partnership Deal with Tabuk Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Inks Partnership Deal with Tabuk Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 16:46 GMT+8 <a href=https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html><strong>SmarterAnalyst</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143781157","content_text":"The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session.\nThe financial terms of the deal have not been disclosed.\nPer the agreement, Tabuk could get the opportunity to distribute other authorized Moderna mRNA products in the future.\nTabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, is a Saudi pharmaceuticals company.\nModerna CEO Stephane Bancel said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia.”\nBancel further added, “It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.” (See Moderna stock analysis on TipRanks)\nOn June 10, Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on the stock but increased the price target to $224 (2.4% upside potential) from $205.\nCann commented, “For a company at Moderna’s stage of development, which is largely pre-approval, we primarily focus on potential future revenue to value the company. Based on our expectation that in addition to its already launched COVID-19 vaccine, Moderna will launch several of its development-stage products in the next six years, we estimate that Moderna’s total revenue will increase to $100.1 billion in 2030.”\nThe rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 6 Buys, 3 Holds, and 2 Sells. The MRNA average analyst price target of $194 implies 11.4% downside potential to current levels. Shares have increased 41.1% over the past six months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184090097,"gmtCreate":1623677019219,"gmtModify":1634030243251,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Done","listText":"Done","text":"Done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/184090097","repostId":"2143965787","repostType":4,"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184004529,"gmtCreate":1623676972361,"gmtModify":1634030244159,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184004529","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184002754,"gmtCreate":1623676912678,"gmtModify":1634030244973,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Wow, how getting better ","listText":"Wow, how getting better ","text":"Wow, how getting better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184002754","repostId":"2143782115","repostType":4,"isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324847970,"gmtCreate":1615986719890,"gmtModify":1703495953990,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324847970","repostId":"2120218579","repostType":4,"isVote":1,"tweetType":1,"viewCount":190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324844332,"gmtCreate":1615986684126,"gmtModify":1703495952430,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"gogo！","listText":"gogo！","text":"gogo！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324844332","repostId":"1128248025","repostType":4,"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":184090097,"gmtCreate":1623677019219,"gmtModify":1634030243251,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Done","listText":"Done","text":"Done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/184090097","repostId":"2143965787","repostType":4,"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184004529,"gmtCreate":1623676972361,"gmtModify":1634030244159,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184004529","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184092857,"gmtCreate":1623677260679,"gmtModify":1634030238160,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184092857","repostId":"2143781157","repostType":4,"repost":{"id":"2143781157","pubTimestamp":1623660416,"share":"https://www.laohu8.com/m/news/2143781157?lang=&edition=full","pubTime":"2021-06-14 16:46","market":"us","language":"en","title":"Moderna Inks Partnership Deal with Tabuk Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2143781157","media":"SmarterAnalyst","summary":"The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharma","content":"<p>The pharmaceutical and biotechnology company <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> (<b>MRNA</b>) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session.</p>\n<p>The financial terms of the deal have not been disclosed.</p>\n<p>Per the agreement, Tabuk could get the opportunity to distribute other authorized Moderna mRNA products in the future.</p>\n<p>Tabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, is a Saudi pharmaceuticals company.</p>\n<p>Moderna CEO Stephane Bancel said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia.”</p>\n<p>Bancel further added, “It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.” (See Moderna stock analysis on TipRanks)</p>\n<p>On June 10, Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on the stock but increased the price target to $224 (2.4% upside potential) from $205.</p>\n<p>Cann commented, “For a company at Moderna’s stage of development, which is largely pre-approval, we primarily focus on potential future revenue to value the company. Based on our expectation that in addition to its already launched COVID-19 vaccine, Moderna will launch several of its development-stage products in the next six years, we estimate that Moderna’s total revenue will increase to $100.1 billion in 2030.”</p>\n<p>The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 6 Buys, 3 Holds, and 2 Sells. The MRNA average analyst price target of $194 implies 11.4% downside potential to current levels. Shares have increased 41.1% over the past six months.</p>\n<p><img src=\"https://static.tigerbbs.com/a7b9b1c14597ff8c93148627f4cdbe23\" tg-width=\"825\" tg-height=\"286\" referrerpolicy=\"no-referrer\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Inks Partnership Deal with Tabuk Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Inks Partnership Deal with Tabuk Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 16:46 GMT+8 <a href=https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html><strong>SmarterAnalyst</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143781157","content_text":"The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session.\nThe financial terms of the deal have not been disclosed.\nPer the agreement, Tabuk could get the opportunity to distribute other authorized Moderna mRNA products in the future.\nTabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, is a Saudi pharmaceuticals company.\nModerna CEO Stephane Bancel said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia.”\nBancel further added, “It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.” (See Moderna stock analysis on TipRanks)\nOn June 10, Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on the stock but increased the price target to $224 (2.4% upside potential) from $205.\nCann commented, “For a company at Moderna’s stage of development, which is largely pre-approval, we primarily focus on potential future revenue to value the company. Based on our expectation that in addition to its already launched COVID-19 vaccine, Moderna will launch several of its development-stage products in the next six years, we estimate that Moderna’s total revenue will increase to $100.1 billion in 2030.”\nThe rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 6 Buys, 3 Holds, and 2 Sells. The MRNA average analyst price target of $194 implies 11.4% downside potential to current levels. Shares have increased 41.1% over the past six months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184002754,"gmtCreate":1623676912678,"gmtModify":1634030244973,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"Wow, how getting better ","listText":"Wow, how getting better ","text":"Wow, how getting better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184002754","repostId":"2143782115","repostType":4,"repost":{"id":"2143782115","pubTimestamp":1623671703,"share":"https://www.laohu8.com/m/news/2143782115?lang=&edition=full","pubTime":"2021-06-14 19:55","market":"sg","language":"en","title":"S'pore stocks start week in the red despite some Covid-19 rules easing","url":"https://stock-news.laohu8.com/highlight/detail?id=2143782115","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Local shares started the week on a slightly dour note despite the e","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Local shares started the week on a slightly dour note despite the easing of some Covid-19 restrictions as part of Singapore's reopening.\nThe benchmark Straits Times ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/spore-stocks-start-week-in-the-red-despite-some-covid-19-rules-easing\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S'pore stocks start week in the red despite some Covid-19 rules easing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS'pore stocks start week in the red despite some Covid-19 rules easing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 19:55 GMT+8 <a href=http://www.straitstimes.com/business/companies-markets/spore-stocks-start-week-in-the-red-despite-some-covid-19-rules-easing><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Local shares started the week on a slightly dour note despite the easing of some Covid-19 restrictions as part of Singapore's reopening.\nThe benchmark Straits Times ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/spore-stocks-start-week-in-the-red-despite-some-covid-19-rules-easing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"http://www.straitstimes.com/business/companies-markets/spore-stocks-start-week-in-the-red-despite-some-covid-19-rules-easing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143782115","content_text":"SINGAPORE (THE BUSINESS TIMES) - Local shares started the week on a slightly dour note despite the easing of some Covid-19 restrictions as part of Singapore's reopening.\nThe benchmark Straits Times Index fell 0.2 per cent or 4.83 points to end Monday at 3,153.14. Across the broader market, advancers outpaced decliners 212 to 182, after some 2.14 billion securities worth $941.5 million changed hands.\nAcross the region, markets generally ended the day in the black. The Nikkei added 0.7 per cent, the KLCI gained 0.5 per cent, while the Kospi rose 0.1 per cent. Hong Kong and Taipei were closed.\nIG senior market strategist Pan Jingyi said some cautious sentiments may linger globally ahead of the US Federal Reserve's Federal Open Market Committee meeting on June 16 as investors weigh the prospects on when it may begin \"tapering discussions\".\nOn the local bourse, Prudential was the top advancer of the day, gaining 11.2 per cent or US$1.71 to finish the day at US$17.02.\nPowermatic Data Systems was another top advancer, rising 26.5 per cent or $0.71 to $3.39.\nMost of the locally listed glove makers were also among the gainers. Top Glove added 1.3 per cent or $0.02 to $1.58; Riverstone Holdings gained 2.3 per cent or $0.03 to $1.35; and UG Healthcare rose 1.6 per cent or $0.01 to $0.62. Newly listed Sri Trang Gloves was among the biggest decliners, losing 5.1 per cent or $0.10 to close at $1.85.\nThe three banks were also among the top losers. UOB lost 0.6 per cent or $0.16 to $25.98; OCBC fell 0.8 per cent or $0.10 to $12.23, and DBS shed 0.2 per cent or $0.07 to $29.66.\nAmos Group was the most actively traded counter for the day. The counter ended Monday up 9.1 per cent or 0.2 Singapore cent at 2.4 cents after some 144.9 million shares changed hands.\nOther heavily traded counters were RH Petrogas, Marco Polo Marine and GSS Energy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324847970,"gmtCreate":1615986719890,"gmtModify":1703495953990,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324847970","repostId":"2120218579","repostType":4,"repost":{"id":"2120218579","pubTimestamp":1615984920,"share":"https://www.laohu8.com/m/news/2120218579?lang=&edition=full","pubTime":"2021-03-17 20:42","market":"us","language":"en","title":"3 Stocks to Buy With Dividends Yielding More than 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120218579","media":"James Brumley","summary":"Investors still have a handful of high-paying options at their disposal if they just think a little outside the box.","content":"<p>Interest rates may be up from the lows they hit in the middle of last year, when the novel coronavirus pandemic was raging. But with rates not too much improved from those record lows, overall stock dividend yields are correspondingly low.</p>\n<p>Thankfully, there are some compelling exceptions to this norm. Among the best opportunities income investors may want to consider today are <b>Iron Mountain</b> (NYSE:IRM), <b>ONEOK</b> (NYSE:OKE), and <b>Artisan Partners Asset Management</b> (NYSE:APAM). Here's a closer look.</p>\n<p><img src=\"https://static.tigerbbs.com/a2302ba0f944ffb7332dd0a711230eb3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Iron Mountain</b></p>\n<p><b>Dividend yield: 6.7%</b></p>\n<p>Iron Mountain's roots are curious, to say the least -- its business is based on storing paperwork for organizations that don't have room to retain those documents on site. For instance, banks are required to keep signed loan papers, but they aren't required to keep those documents right behind the counter.</p>\n<p>The company has expanded its offerings since its 1951 inception, adding related services like document shredding and even the safe storage of artwork. It's also adapted to the digitalization of the workplace, providing document scanning services and cloud data backup, just to name a few items on its more modern menu. Not only are all of these offerings perpetually marketable, but its services are cross-marketable. That is to say, users of <a href=\"https://laohu8.com/S/AONE\">one</a> of its services are likely to need another.</p>\n<p>That's not the nuance that makes Iron Mountain such a reliable dividend name, however. The big selling feature here is the nature of the business. Organizations pay an ongoing fee to Iron Mountain for its services, which are relatively easy (read: inexpensive) to maintain once they're set up. In other words, there's time and trouble involved in bringing a load of paperwork to a warehouse where it must be shelved. Once it's on that shelf, though, the company's customers mostly pay Iron Mountain to sit on it.</p>\n<p>There's not a ton of growth in the business, but there's lots of regular, predictable cash flow. And because Iron Mountain is structured as a real estate investment trust (REIT), it's required to pay out at least 90% of taxable income to shareholders. End result? The company hasn't failed to pay a dividend in any quarter since early 2010.</p>\n<p><b>ONEOK</b></p>\n<p><b>Dividend yield: 7.2%</b></p>\n<p>Most investors might know crude oil and natural gas prices tanked in the first half of last year, largely on fears of a coronavirus-induced recession. What they may not realize, though, is that demand for gas and oil never actually slumped to any meaningful degree. The U.S. Energy Information Administration estimates worldwide consumption of crude only fell 9% in 2020, with much of that contraction linked to logistics hurdles rather than demand issues. The EIA further estimates U.S. consumption of natural gas fell last year as well, though only about 2%.</p>\n<p>The data highlights an important reality of the energy market: Not all energy stocks are the same. Explorers and producers are tremendously affected by plunging hydrocarbon values, as the cost of drilling and extracting is the same regardless of the sales price of the gas and oil being extracted and delivered. The cost of delivering that gas and oil, however, holds pretty steady.</p>\n<p>Enter ONEOK, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the nation's leading natural gas pipeline and processing companies. It's paid by the cubic foot for gas it gathers, processes, or transports regardless of that gas's value at the time.</p>\n<p>The business's resiliency is evident in last year's results. Despite plunging gas and crude prices, ONEOK's 2020 EBITDA was 6% better than 2019's despite the demand headwind. The company is calling for rebounding volumes this year, too.Granted, this resiliency and bright outlook didn't prompt ONEOK to up its dividend beginning with the first payout of 2020, as it usually does. That decision, however, doesn't necessarily preclude the company from doing so at a later date this year. Perhaps more important. ONEOK hasn't failed to pay a dividend in any quarter since the early '70s.</p>\n<p>Best of all, it can afford to pay the dividends it's dishing out. While ONEOK's operating per-share earnings are historically less than than its dividend, in the capital-intensive gas pipeline business, distributable cash flow (or DCF) is a much more accurate measure of how well supported a payout is. Despite last year's challenges, the company's 2020 DCF of about $4.38 was more than enough to fund the dividend of $3.74. The same story goes for previous years.</p>\n<p><b>Artisan Partners Asset Management</b></p>\n<p><b>Dividend yield: 6.2%</b></p>\n<p>Finally, have you ever heard of the Artisan family of mutual funds? You can also invest in the company that manages them, collecting a piece of the fees it collects every quarter for the assets under the company's management umbrella.</p>\n<p>Artisan Partners' business model is quite a bit like Iron Mountain's, in that the company collects ongoing revenue for providing a modicum of service to existing customers without necessarily bringing in new ones. That's not to say Artisan doesn't strive to add new investments in its funds, nor is it to suggest investors don't close out their positions in these funds on a regular basis. Heck, even the market's ebb and flow affects the value of the investment pools the fund company bases its quarterly management fees on.</p>\n<p>On balance, though, the corresponding cash flow is pretty steady even if absolute growth isn't. Indeed, the company hasn't failed to produce a profit in any quarter since it went public back in 2013. This has allowed the asset manager to pay a reliable, healthy dividend every quarter since then, even if the amount of the payout hasn't been completely predictable.</p>\n<p>Artisan Partners brings something else to the table in the meantime: value. Shares are priced at a palatable 15 times earnings for the past 12 months and only 11 times the coming year's projected per-share profits. The stock is also priced 16% under analysts' current consensus target, opening the door to some price appreciation while investors collect their above-average dividends.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy With Dividends Yielding More than 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy With Dividends Yielding More than 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 20:42 GMT+8 <a href=https://www.fool.com/investing/2021/03/17/3-stocks-to-buy-with-dividends-yielding-more-than/><strong>James Brumley</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Interest rates may be up from the lows they hit in the middle of last year, when the novel coronavirus pandemic was raging. But with rates not too much improved from those record lows, overall stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/17/3-stocks-to-buy-with-dividends-yielding-more-than/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OKE":"欧尼克（万欧卡）","IRM":"爱恩铁山","APAM":"Artisan Partners Asset Managemen"},"source_url":"https://www.fool.com/investing/2021/03/17/3-stocks-to-buy-with-dividends-yielding-more-than/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2120218579","content_text":"Interest rates may be up from the lows they hit in the middle of last year, when the novel coronavirus pandemic was raging. But with rates not too much improved from those record lows, overall stock dividend yields are correspondingly low.\nThankfully, there are some compelling exceptions to this norm. Among the best opportunities income investors may want to consider today are Iron Mountain (NYSE:IRM), ONEOK (NYSE:OKE), and Artisan Partners Asset Management (NYSE:APAM). Here's a closer look.\n\nImage source: Getty Images.\nIron Mountain\nDividend yield: 6.7%\nIron Mountain's roots are curious, to say the least -- its business is based on storing paperwork for organizations that don't have room to retain those documents on site. For instance, banks are required to keep signed loan papers, but they aren't required to keep those documents right behind the counter.\nThe company has expanded its offerings since its 1951 inception, adding related services like document shredding and even the safe storage of artwork. It's also adapted to the digitalization of the workplace, providing document scanning services and cloud data backup, just to name a few items on its more modern menu. Not only are all of these offerings perpetually marketable, but its services are cross-marketable. That is to say, users of one of its services are likely to need another.\nThat's not the nuance that makes Iron Mountain such a reliable dividend name, however. The big selling feature here is the nature of the business. Organizations pay an ongoing fee to Iron Mountain for its services, which are relatively easy (read: inexpensive) to maintain once they're set up. In other words, there's time and trouble involved in bringing a load of paperwork to a warehouse where it must be shelved. Once it's on that shelf, though, the company's customers mostly pay Iron Mountain to sit on it.\nThere's not a ton of growth in the business, but there's lots of regular, predictable cash flow. And because Iron Mountain is structured as a real estate investment trust (REIT), it's required to pay out at least 90% of taxable income to shareholders. End result? The company hasn't failed to pay a dividend in any quarter since early 2010.\nONEOK\nDividend yield: 7.2%\nMost investors might know crude oil and natural gas prices tanked in the first half of last year, largely on fears of a coronavirus-induced recession. What they may not realize, though, is that demand for gas and oil never actually slumped to any meaningful degree. The U.S. Energy Information Administration estimates worldwide consumption of crude only fell 9% in 2020, with much of that contraction linked to logistics hurdles rather than demand issues. The EIA further estimates U.S. consumption of natural gas fell last year as well, though only about 2%.\nThe data highlights an important reality of the energy market: Not all energy stocks are the same. Explorers and producers are tremendously affected by plunging hydrocarbon values, as the cost of drilling and extracting is the same regardless of the sales price of the gas and oil being extracted and delivered. The cost of delivering that gas and oil, however, holds pretty steady.\nEnter ONEOK, one of the nation's leading natural gas pipeline and processing companies. It's paid by the cubic foot for gas it gathers, processes, or transports regardless of that gas's value at the time.\nThe business's resiliency is evident in last year's results. Despite plunging gas and crude prices, ONEOK's 2020 EBITDA was 6% better than 2019's despite the demand headwind. The company is calling for rebounding volumes this year, too.Granted, this resiliency and bright outlook didn't prompt ONEOK to up its dividend beginning with the first payout of 2020, as it usually does. That decision, however, doesn't necessarily preclude the company from doing so at a later date this year. Perhaps more important. ONEOK hasn't failed to pay a dividend in any quarter since the early '70s.\nBest of all, it can afford to pay the dividends it's dishing out. While ONEOK's operating per-share earnings are historically less than than its dividend, in the capital-intensive gas pipeline business, distributable cash flow (or DCF) is a much more accurate measure of how well supported a payout is. Despite last year's challenges, the company's 2020 DCF of about $4.38 was more than enough to fund the dividend of $3.74. The same story goes for previous years.\nArtisan Partners Asset Management\nDividend yield: 6.2%\nFinally, have you ever heard of the Artisan family of mutual funds? You can also invest in the company that manages them, collecting a piece of the fees it collects every quarter for the assets under the company's management umbrella.\nArtisan Partners' business model is quite a bit like Iron Mountain's, in that the company collects ongoing revenue for providing a modicum of service to existing customers without necessarily bringing in new ones. That's not to say Artisan doesn't strive to add new investments in its funds, nor is it to suggest investors don't close out their positions in these funds on a regular basis. Heck, even the market's ebb and flow affects the value of the investment pools the fund company bases its quarterly management fees on.\nOn balance, though, the corresponding cash flow is pretty steady even if absolute growth isn't. Indeed, the company hasn't failed to produce a profit in any quarter since it went public back in 2013. This has allowed the asset manager to pay a reliable, healthy dividend every quarter since then, even if the amount of the payout hasn't been completely predictable.\nArtisan Partners brings something else to the table in the meantime: value. Shares are priced at a palatable 15 times earnings for the past 12 months and only 11 times the coming year's projected per-share profits. The stock is also priced 16% under analysts' current consensus target, opening the door to some price appreciation while investors collect their above-average dividends.","news_type":1},"isVote":1,"tweetType":1,"viewCount":190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324844332,"gmtCreate":1615986684126,"gmtModify":1703495952430,"author":{"id":"3577012862693100","authorId":"3577012862693100","name":"ReaganMama","avatar":"https://static.tigerbbs.com/3aef6e2121d0e4abf86f28ed149ce8fb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577012862693100","idStr":"3577012862693100"},"themes":[],"htmlText":"gogo！","listText":"gogo！","text":"gogo！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324844332","repostId":"1128248025","repostType":4,"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
